Compare Ginkgo Bioworks Holdings Inc (DNA) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Global Payments Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Global Payments Inc trades at $88.53 (market cap $22.72B). The key difference: Global Payments Inc is far larger — about 44.9× Ginkgo Bioworks Holdings Inc's market cap, and Global Payments Inc pays a 1.16% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | GPN | |
|---|---|---|
Market Cap | $505.73M | $22.72B |
Sector | Health | Industrials |
52-Week High | $16.14 | $90.01 |
52-Week Low | $5.48 | $62.47 |
Enterprise Value | $607.68M | $40.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Global Payments (GPN) trades at $88.65, up 2.93% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 63.91% gross margin but negative net income margin and ROE. Recent Q2 2026 EPS of $3.46 beat estimates, though revenue guidance was trimmed. Analyst consensus is a Buy with a $96.67 target.
GPN offers upside to analyst targets but faces risks from margin pressure and competitive fintech landscape. Debt-to-asset ratio rose to 41.57% in 2025, increasing financial leverage concerns. Investment appeal hinges on execution of the Genius platform strategy amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
